ASIT biotech announced its Phase IIa double-blind placebo-controlled clinical study in house dust mite-induced rhinoconjunctivitis has completed its clinical phase. This first clinical trial in house dust mite rhinitis was undertaken by the team led by Professor Bettina Hauswald, principal investigator, at the Carl Gustav Carus University Hospital in Dresden, Germany. Of the 37% who began the treatment with hdm-ASIT+™, 33 attended the last visit to the allergist, giving a retention rate of 89%. The main objectives of this study are to evaluate the drug candidate’s safety and tolerability profile and to determine the maximum cumulative dose tolerated by house dust mite allergic patients. The secondary objectives of this study are the assessment of the impact of hdm-ASIT+™ on the immune system and on the reduction of the reactivity to a conjunctival provocation test2. During the trial, no major treatment-related adverse event was observed, even at the higher allergen dose, which is 200 times greater than the first dose administered. ASIT biotech is currently cleaning the clinical database. This first step will be followed by the statistical analysis of the data and the publication of the clinical results by the end of the first quarter of 2017. This research program is partly funded by the Walloon region in the form of recoverable advances, in accordance with the agreement signed at the beginning of 2016. A test enabling both the diagnosis of a patient’s allergy and the determination of their level of hypersensitivity at various times during the desensitization process. hdm-ASIT+TM product candidate for the treatment of house dust mite allergy consists of a mixture of natural allergen fragments obtained from a purified specific proteinic extract from house dust mite.